Logo
x

Search

Subscribe Now

Nivolumab

PharmaShots Interview: BMS' Dr. Ian Waxman Shares Insights on the Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC

PharmaShots Interview: BMS' Dr. Ian Waxman Shares Insights on the Opdivo (nivolumab) + Yervoy (ipilimumab) for dMMR or MSI-H mCRC

  • September 28, 2021
Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Takeda and Ono's Opdivo (nivolumab) + Cabometyx (cabozantinib) Receive MHLW's Approval for the Treatment of Unresectable or Metast...

  • August 25, 2021
BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

  • August 23, 2021
BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell Carcinoma

BMS Reports EMA's Validation of MAA for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + CT to Treat Esophageal Squamous Cell...

  • August 17, 2021
PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced Renal Cell Carcinoma

PharmaShots Interview: Ipsen's Dr. Med. Steven Hildemann Shares Insight on the EC's Approval of Cabometyx + Nivolumab for Advanced...

  • May 11, 2021
BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metastatic or Unresectable Melanoma

BMS Report Results of Relatlimab + Opdivo (nivolumab) in P-II/III RELATIVITY-047 Study in Patients with Previously Untreated Metas...

  • March 26, 2021
BMS Receives EMA’s Validation for Opdivo (nivolumab) in Combination with Chemotherapy for the Treatment of Urothelial Carcinoma

    BMS Receives EMA’s Validation for Opdivo (nivolumab) in Combination with Chemotherapy for the Treatment of Urothelial Carcinoma

    • October 31, 2023
    BMS Reports P-III Trial (CheckMate -67T) Results of Nivolumab (nivolumab and hyaluronidase) for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

      BMS Reports P-III Trial (CheckMate -67T) Results of Nivolumab (nivolumab and hyaluronidase) for Advanced or Metastatic Clear Cell...

      • October 20, 2023
      BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval as Adjuvant Treatment for Completely Resected Stage IIB or Stage IIC Melanoma

        BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval as Adjuvant Treatment for Completely Resected Stage IIB or Stage IIC Melano...

        • October 16, 2023
        BMS Reports P-III Trial (CheckMate -77T) Results of Neoadjuvant Opdivo (nivolumab) + CT for Resectable Non-Small Cell Lung Cancer

          BMS Reports P-III Trial (CheckMate -77T) Results of Neoadjuvant Opdivo (nivolumab) + CT for Resectable Non-Small Cell Lung Cancer

          • September 22, 2023
          BMS’ Opdivo (nivolumab) Receives EC’s Approval as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma

            BMS’ Opdivo (nivolumab) Receives EC’s Approval as an Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma

            • August 23, 2023
            BMS Receives EMA’s CHMP Positive Opinion Recommending Approval of Opdivo (nivolumab) for Completely Resected Stage IIB or IIC Melanoma

              BMS Receives EMA’s CHMP Positive Opinion Recommending Approval of Opdivo (nivolumab) for Completely Resected Stage IIB or IIC Mela...

              • July 21, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.